NUVB at a glance
Nuvation Bio Inc. (NUVB, SEC CIK 1811063) filed its latest 10-K annual report on March 2, 2026, a 10-Q quarterly report on August 6, 2026, an 8-K current report on August 6, 2026 and Form 4 insider filings as recently as August 21, 2026. SignalX summarizes each filing with AI and tracks the company's insider trades and institutional holders.
- For the fiscal year ended December 31, 2025 (FY2025), Nuvation Bio Inc. (NUVB) reported revenue of $62.9 million (up 699.0% from FY2024) and a net loss of $204.6 million. Diluted EPS was -$0.60.
- As of June 30, 2026, 31 institutional investment managers tracked by SignalX reported holding Nuvation Bio Inc. (NUVB) shares worth $707.2 million in 13F-HR filings.
- The most recent insider open-market sale reported on Form 4 was by Hattersley Gary on August 19, 2026 of 100,000 shares at $7.09 per share.
- In the last 90 days, NUVB insiders reported 0 open-market purchases ($0) and 1 open-market sale ($709K) on Form 4, a net sale of $709K.
Source: SEC EDGAR (XBRL financial data, 13F-HR and Form 4 filings).
- Revenue · FY2025
- $62.9M
- +699.0% vs prior year
- Insiders · 90 days
- 0 buys · 1 sell
- Net −$709K
- 13F holders
- 31 funds
- $707.2M · +0 vs prior quarter
- Latest 8-K
- Aug 6, 2026
- Item 2.02
AI 10-K Annual Report Analysis
Latest 10-K, fiscal year ended Dec 31, 2025
Business Overview
- Core business: Global oncology focused on developing novel small molecule therapies for difficult-to-treat cancers, leveraging medicinal chemistry and clinical data
- New emphasis: U.S. commercial launch of IBTROZI (taletrectinib) for ROS1+ NSCLC approved June 2025, plus new Eisai partnership for European and other territories in 2026
- Strategic shift: Expansion into global commercialization via partnerships in China, Japan, Europe, and additional territories, extending reach beyond prior regional focus
- Quantitative highlight: 71 U.S. commercial field team members for IBTROZI launch, with nearly 300 patients enrolled in pivotal Phase 2 global clinical trial program
- Noteworthy: Median duration of response for IBTROZI matured to 50 months by August 2025, supporting its potential as new standard of care in ROS1+ NSCLC
Risk Factors
- Regulatory risk: FDA approval and post-approval obligations for IBTROZI (taletrectinib) granted June 11, 2025 for ROS1+ NSCLC treatment
- Geopolitical risk: Commercial partnerships in Japan (NK) and China (Innovent) expose revenue to MHLW and NMPA regulatory environments
- Operational risk: High R&D expenses increased by $16M in 2025 driven by clinical trial costs and headcount growth, with continued need for funding
- Competitive risk: Phase 3 TRUST-III study compares taletrectinib to crizotinib in China, a key competitor in ROS1+ NSCLC market
- Financial risk: $250M non-dilutive financing includes $150M synthetic royalty financing with tiered royalties up to 2.0x investment, plus $100M senior secured loan at SOFR+6% interest
Management Discussion & Analysis
- Revenue and profitability data not disclosed in MD&A section
- No cash flow, buybacks, dividends, or capex information given
- Forward-looking statements caution on risks causing actual results to differ materially
AI summary of the NUVB 10-K filed . Generated from the filing text; verify against the original.View on SEC EDGARHow to read a 10-K
AI 10-Q Quarterly Report Analysis
Latest 10-Q, quarter ended Jun 30, 2026
Management Discussion & Analysis
- Revenue $31.7M, up $26.9M YoY from $4.8M, driven by IBTROZI product revenue of $23.2M
- Collaboration revenue $8.5M, up $4.9M YoY, led by product supply and royalty revenue increases
- Total costs $82.7M, up $14.3M YoY, with R&D $30.7M and SG&A $42.6M
- Cash, equivalents and marketable securities $661.0M; $279.1M notes proceeds and $58.7M debt repayment
- FDA supplemental IBTROZI application target action date January 4, 2027; expenses expected to increase substantially
Risk Factors
- Newly added commercialization risk triggered by June 2025 FDA approval and U.S. launch of IBTROZI, the company’s only FDA-marketed product
- Most material update: limited commercial experience now threatens launch execution, sales-force sizing, distribution, and near-term profitability
- Regulatory risk: U.S. and China approvals carry post-marketing requirements and commitments, with potential penalties or withdrawal for noncompliance
- Competitive risk: safer, cheaper, or more convenient ROS1+ NSCLC therapies could reduce IBTROZI adoption and commercial viability
- Financial risk: profitability depends primarily on IBTROZI sales, while indebtedness and debt-service obligations may constrain operating funding
AI summary of the NUVB 10-Q filed . Generated from the filing text; verify against the original.View on SEC EDGAR10-K vs 10-Q vs 8-K
AI 8-K Current Report Analysis
The most recent material events, by 8-K item
Item 2.02: Results of Operations and Financial Condition
- Q2 2026 financial results released for quarter ended June 30, 2026
- Full operating metrics and financial details contained in Exhibit 99.1
Item EX-99.1: Item EX-99.1
- Q2 revenue $31.7M, including $23.2M IBTROZI product sales, signaling accelerating commercial adoption
- IBTROZI sales grew 25% QoQ, with approximately 85% of 160 new starts TKI-naïve
Item 1.01: Entry into a Material Definitive Agreement
- Additional capped calls executed July 1, 2026, tied to the Greenshoe Exercise
- Designed to reduce potential Class A common-stock dilution upon convertible-note conversion
Item 2.03: Creation of a Direct Financial Obligation
- Total convertible debt increased to $287.5M, including the fully exercised $37.5M greenshoe option
- 0.75% annual interest, semiannual payments beginning January 1, 2027, with maturity on July 1, 2032
Item 8.01: Other Events
- Forward-looking statements concern Nuvation Bio’s planned use of remaining net proceeds from its offering
- Plans remain subject to market conditions, trends, and other risks identified in the company’s SEC filings
Item EX-99.1: Item EX-99.1
- Greenshoe fully exercised, increasing convertible notes offering to $287.5 million
- Notes carry 0.75% interest and mature in 2032, adding low-cost long-term financing
Item 1.01: Entry into a Material Definitive Agreement
- Nuvation Bio prepaid approximately $58.5 million covering principal, interest, fees, costs and expenses
- Loan Agreement obligations, covenants and liabilities fully discharged on June 30, 2026
Item 8.01: Other Events
- $250.0 million aggregate principal amount of notes offered
- Underwriters hold a $37.5 million over-allotment option
Item EX-99.1: Item EX-99.1
- Proposed $200M convertible senior notes due July 1, 2032, plus underwriters’ $30M over-allotment option
- Proceeds earmarked for capped calls, full repayment of senior secured loan, and general corporate purposes
AI summaries of NUVB 8-K current reports filed with the SEC. What 8-K item codes mean
SignalX for NUVB
Don't miss the next NUVB filing
- Alerts as it files. A push when NUVB files an 8-K or an insider trades.
- Fund moves. Which tracked funds opened, added or cut NUVB, by share count.
- Ask anything. An AI agent that reads every NUVB filing and answers with sources.
NUVB alerts on your phone. Follow it in the SignalX Android app.
Recent Insider Transactions (Form 4)
Latest reported trades by officers, directors and 10% owners
| Insider | Type | Date | Shares | Price |
|---|---|---|---|---|
| Hattersley Gary | M | Aug 19, 2026 | 100,000 | - |
| Hattersley Gary | M | Aug 19, 2026 | 100,000 | $1.87 |
| Hattersley Gary | Sell | Aug 19, 2026 | 100,000 | $7.09 |
| Sauvage Philippe | M | Jul 15, 2026 | 1 | $1.97 |
| Sauvage Philippe | M | Jul 15, 2026 | 1 | - |
| Sauvage Philippe | M | Jul 15, 2026 | 39,999 | $2.17 |
| Sauvage Philippe | M | Jul 15, 2026 | 39,999 | - |
| Markel Stacy | M | Jun 23, 2026 | 90,380 | - |
Financial SummaryXBRL
| Metric | FY2023 | FY2024 | FY2025 |
|---|---|---|---|
| Profitability | |||
| Revenue | $0 | $7.9M | $62.9M |
| Gross Profit | $0 | $795K | - |
| Operating Income | - | -$592.6M | -$213.1M |
| Net Income | - | -$567.9M | -$204.6M |
| Gross Margin | - | 10.1% | - |
| Op. Margin | - | -7527.3% | -338.7% |
| Net Margin | - | -7213.8% | -325.3% |
| Balance Sheet | |||
| Total Assets | - | $540.6M | $594.8M |
| Equity | $605.1M | $463.8M | $305.7M |
| ROE | - | -122.5% | -66.9% |
| Per Share | |||
| EPS | $-0.35 | $-2.11 | $-0.60 |
| Cash Flow | |||
| Operating CF | -$68.0M | -$130.4M | -$173.4M |
Source: XBRL data in Nuvation Bio Inc. (NUVB)'s 10-K filings on SEC EDGAR, in USD. Compare across companies →
13F Fund Holdings: Quarterly Trend
Latest: Q2 2026Aggregate NUVB share value held by 13F filers tracked by SignalX, by quarter.
Quarterly totals table
| Quarter | Funds | Total value |
|---|---|---|
| Q2 2026 | 31 | $707.2M |
| Q1 2026 | 31 | $516.4M |
| Q4 2025 | 28 | $1.06B |
| Q3 2025 | 27 | $449.0M |
| Q2 2025 | 27 | $238.8M |
| Q1 2025 | 23 | $153.0M |
| Q4 2024 | 18 | $205.8M |
| Q3 2024 | 16 | $35.6M |
- BlackRock+2.53M (+10%)
- Renaissance Technologies LLC+786.8K (+141%)
- D.E. Shaw & Co+747.0K (+190%)
- State Street Corp+585.9K (+9%)
- Vanguard Portfolio Management LLC+413.2K (+18%)
- Two Sigma Investments−1.44M (-53%)
- Millennium Management−749.3K (-67%)
- Morgan Stanley−413.9K (-22%)
- Citigroup−102.0K (-32%)
- Citadel Advisors LLC−77.1K (-4%)
Source: 13F-HR filings on SEC EDGAR (aggregated from 201 fund-quarter rows). Reflects only 13F filers tracked by SignalX, not the full institutional ownership universe. How 13F filings work
NUVB filing archive
AI analysis pages for each 10-K, 10-Q and 8-K
10-K annual reports
10-Q quarterly reports
Latest 2026 SEC Filings: 10-K, 10-Q, 8-K & Form 4
| Form | Filing date | Period | Analysis | SEC |
|---|---|---|---|---|
| 4 | Aug 21, 2026 | - | - | - |
| 8-K | Aug 6, 2026 | - | Analysis | - |
| 10-Q | Aug 6, 2026 | Jun 30, 2026 | Analysis | |
| 4 | Jul 17, 2026 | - | - | - |
| 8-K | Jul 6, 2026 | - | Analysis | - |
| 8-K | Jun 30, 2026 | - | Analysis | - |
| 4 | Jun 24, 2026 | - | - | - |
| 4 | Jun 24, 2026 | - | - | - |
| 4 | Jun 24, 2026 | - | - | - |
| 4 | Jun 11, 2026 | - | - | - |
| 8-K | May 27, 2026 | - | Analysis | |
| 4 | May 26, 2026 | - | - | |
| 4 | May 26, 2026 | - | - | |
| 4 | May 26, 2026 | - | - | |
| 4 | May 26, 2026 | - | - | |
| 4 | May 26, 2026 | - | - | |
| 4 | May 26, 2026 | - | - | |
| 4 | May 26, 2026 | - | - | |
| 8-K | May 4, 2026 | - | Analysis | - |
| 10-Q | May 4, 2026 | Mar 31, 2026 | Analysis | |
| 4 | Apr 21, 2026 | - | - | - |
| 4 | Apr 21, 2026 | - | - | - |
| 4 | Apr 8, 2026 | - | - | - |
| 4 | Mar 3, 2026 | - | - | - |
| 4 | Mar 3, 2026 | - | - | - |
Related Health Care companies
- AARD · Aardvark Therapeutics, Inc.Pharmaceutical Preparations
- ABT · Abbott LaboratoriesPharmaceutical Preparations
- ABBV · AbbVie IncPharmaceutical Preparations
- ABEO · ABEONA THERAPEUTICS INC.Pharmaceutical Preparations
- ACAD · ACADIA PHARMACEUTICALS INCPharmaceutical Preparations
- ACRS · Aclaris Therapeutics, Inc.Pharmaceutical Preparations
- ACTU · ACTUATE THERAPEUTICS, INC.Pharmaceutical Preparations
- ADCT · ADC Therapeutics SAPharmaceutical Preparations
NUVB SEC filings: frequently asked questions
Are NUVB insiders buying or selling?
In the last 90 days, Nuvation Bio Inc. (NUVB) officers, directors and 10% owners reported no open-market purchases and 1 open-market sale worth $709,240 by 1 insider on Form 4. Many insider sales are pre-planned or for taxes, so purchases usually carry more information.
Which institutions hold NUVB stock?
As of June 30, 2026, the largest Nuvation Bio Inc. (NUVB) holders among the 13F filers tracked by SignalX were FMR LLC (Fidelity) ($296.7 million), BlackRock ($156.9 million), Vanguard Capital Management LLC ($67.7 million), State Street Corp ($41.9 million), Bank of America Corp ($20.0 million). 13F-HR reports are filed up to 45 days after each quarter ends.
What was NUVB's revenue in fiscal year 2025?
For the fiscal year ended December 31, 2025 (FY2025), Nuvation Bio Inc. (NUVB) reported revenue of $62.9 million (up 699.0% from FY2024) and a net loss of $204.6 million. Diluted EPS was -$0.60. The figures come from the XBRL data in the 10-K.
What are the main risks in NUVB's latest 10-K?
In the 10-K filed March 2, 2026, Nuvation Bio Inc. (NUVB) flagged: Regulatory risk: FDA approval and post-approval obligations for IBTROZI (taletrectinib) granted June 11, 2025 for ROS1+ NSCLC treatment. Geopolitical risk: Commercial partnerships in Japan (NK) and China (Innovent) expose revenue to MHLW and NMPA regulatory environments. (AI summary of the Risk Factors section.)
What did NUVB report in its latest 8-K?
Nuvation Bio Inc. (NUVB) filed an 8-K on August 6, 2026 reporting Item 2.02 (Results of Operations and Financial Condition). Q2 2026 financial results released for quarter ended June 30, 2026.
What are the latest NUVB SEC filings?
Nuvation Bio Inc. (NUVB) filed its latest 10-K annual report on March 2, 2026, a 10-Q quarterly report on August 6, 2026, an 8-K current report on August 6, 2026 and a Form 4 insider filing on August 21, 2026.
What is NUVB's SEC CIK number?
Nuvation Bio Inc. (NUVB)'s SEC Central Index Key (CIK) is 1811063. EDGAR lists every NUVB filing under that number.
Ask anything about NUVB
The research agent reads NUVB's filings, financials, insider trades and 13F holders, then answers with sources.